Tag Archives: FDA

Provectus Biopharmaceuticals Inc (OTCMKTS:PVCT) ran up to the tune of 22% on Friday, as the company announced the reestablishing of a Strategic Advisory Board (SAB). The news marks what many will see as a key step in the transitioning of Provectus...

Interpace Diagnostics Group Inc (NASDAQ:IDXG) is all over the place right now. The company announced at the start of the week that it as picked up some coverage on its lead asset (well, one of then), and started to run on the back of the news....

Pharmacyte Biotech Inc (OTCMKTS:PMCB) just reported that it’s the recipient of what’s called the Pipelines of Promise Award from BIO International. There are a few benefits associated with this award, including what looks like some...

XOMA Corporation (NASDAQ:XOMA) just jumped on some fresh news relating to one of its preclinical programs, and is trading around 15% up on its start of the week pricing heading into the Wednesday morning open in the US. That’s a nice...

The management team over at CytoDyn Inc (OTCMKTS:CYDY) are set to host a conference call later on today, aimed at discussing the progress of the company’s development pipeline and so called regulatory developments associated with the...

When we first looked at US Stem Cell Inc (OTCMKTS:USRM), we urged our readers to look beyond the metrics, and to try and form a bias based on what the company was trying to achieve, and in what space. At the time (beginning of March this year),...

At the end of March, we asked the question ‘Can Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) Continue To Run?’ as part of this piece. We concluded that the spate of catalysts that are set to hit press over the coming six to twelve...

Galectin Therapeutics Inc (NASDAQ:GALT) was a big first quarter winner. The company opened 2017 in and around the dollar mark, and currently trades for around $3.7 – a 185% appreciation during the period. There have been a couple of value-add...

22nd Century Group Inc (NYSEMKT:XXII) is a stock we’ve come back to on a number of occasions here at Insider Financial, with our most recent coverage being this piece from the start of January. Our basic thesis on the company was that...

In our late March coverage of HTG Molecular Diagnostics Inc (NASDAQ:HTGM), we argued that run we’d seen to that date was representative of a longer term (and long time coming) revaluation in a stock that had been overlooked (and in turn,...

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter